The AIM technology has been designed to orchestrate specific immune system responses in a highly controllable and reproducible way independent of the healthiness or abundance of the patient’s natural antigen presenting cell (APC) population. Natural APCs are major players in the body’s immune system as they direct the immune system cells in attacks on specifically targeted antigens and cells. However, under certain disease conditions, natural APCs can be damaged, absent or inactive.
The AIM technology holds great potential for use in immuno-therapy because aAPCs can be readily engineered in such a way that a highly specific immune attack can be directed toward any foreign substance or cell type in a patient’s body.
NexImmune executives will attend the JP Morgan Healthcare Conference on January 13-14, 2014 in San Francisco.
BioPharm America 2013
Sept 2013 - NexImmune executives attended BioPharm America in Boston from September 17-19, 2013.
July 2013 - NexImmune received an SBIR grant of $290,000 from the NIH for the development of a human therapeutic based on AIM Technology.
State of Maryland Grant
July 2013 - NexImmune received an extension of its translational R&D grant for $125,000 from the state.